Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) Operating Expenses (2016 - 2025)

CorMedix has reported Operating Expenses over the past 15 years, most recently at $48.2 million for Q4 2025.

  • Quarterly results put Operating Expenses at $48.2 million for Q4 2025, up 181.79% from a year ago — trailing twelve months through Dec 2025 was $125.6 million (up 100.53% YoY), and the annual figure for FY2025 was $125.6 million, up 100.53%.
  • Operating Expenses reached $48.2 million in Q4 2025 per CRMD's latest filing, up from $41.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $48.2 million in Q4 2025 and bottomed at $5.9 million in Q2 2021.
  • Median Operating Expenses over the past 5 years was $11.4 million (2023), compared with a mean of $14.9 million.
  • The largest annual shift saw Operating Expenses plummeted 34.11% in 2021 before it surged 196.9% in 2025.
  • Over 5 years, Operating Expenses stood at $7.8 million in 2021, then rose by 8.09% to $8.4 million in 2022, then skyrocketed by 86.12% to $15.7 million in 2023, then grew by 9.12% to $17.1 million in 2024, then soared by 181.79% to $48.2 million in 2025.
  • Business Quant data shows Operating Expenses for CRMD at $48.2 million in Q4 2025, $41.7 million in Q3 2025, and $18.3 million in Q2 2025.